Methotrexate Market size was USD 9.6 billion in 2024 and is estimated to reach USD 15.1 billion by the end of 2037, expanding at a CAGR of 3.6% during the forecast period, i.e., 2025-2037. In 2025, the industry size of methotrexate is evaluated at USD 9.9 billion.
The rising prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is augmenting the consumption of methotrexate solutions. For instance, according to the National Psoriasis Foundation, millions of people across the world are living with psoriatic arthritis, and around 2% to 3% of the total population have psoriasis. The report by the Global Psoriasis Atlas reveals that an estimated 60 million individuals are living with psoriasis, globally. Furthermore, the Global RA Network reveals that around 350 million people worldwide are living with arthritis issues. 1 in 100 people often are diagnosed with rheumatoid arthritis and if not treated are leading to work disability.
For instance, in January 2024, Novartis AG one of the leading manufacturers of methotrexate solutions revealed that its robust operational performance led to huge double-digit top and bottom-line growth. The company estimates 40.0%+ margin growth by 2027 and 5.0% cc CAGR between 2023 and 2028. Furthermore, the net sales increased by +10.0% with core operating income growth of +18.0%. Cardiovascular-renal-metabolic, immunology, neuroscience, and oncology are four core therapeutic areas driving the company’s growth.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
3.6% |
|
Base Year Market Size (2024) |
USD 9.6 billion |
|
Forecast Year Market Size (2037) |
USD 15.1 billion |
|
Regional Scope |
|
Application (Cancer Treatment, Autoimmune Diseases, Psoriasis)
The cancer treatment segment is likely to capture methotrexate market share of over 54.3% by 2037. The increasing cases of cancer are pushing the demand for methotrexate drugs for effective treatment. The World Health Organization (WHO) reveals that around 20 million new cancer cases were diagnosed in 2022. Also, the same source estimates that one in five individuals experience cancer growth in their lifetime. Manufacturers’ continuous focus on innovations is leading to the development of advanced and effective anti-cancer methotrexate solutions. For instance, in August 2024, STAQ Pharma announced the expansion of its oncology portfolio starting with methotrexate. The methotrexate solution is widely used for the treatment of pediatric cancer patients.
Formulation (Tablet, Injection, Liquid)
The tablet segment is expected to hold a dominating methotrexate market share throughout the projected period. Convenience and accurate dosage are prime factors driving the sales of methotrexate tablets. The pediatric and older patient demographics find tablets a more convenient form of administration than injections. The quick effect and cost-effectiveness are other aspects augmenting the demand for methotrexate tablets. Considering these drivers, manufacturers are more concentrated on the development of methotrexate tablets than other formulations. For instance, in August 2024, Elite Pharmaceuticals, Inc. announced the introduction of generic methotrexate sodium 2.5 mg tablets. These tablets are used for acute lymphoblastic leukemia treatment among adults.
Our in-depth analysis of the global methotrexate market includes the following segments:
|
Application |
|
|
Formulation |
|
|
Distribution Channel |
|
|
End use |
|
North America Market Forecast
In methotrexate market, North America region is likely to hold more than 33.7% revenue share by 2037. The presence of advanced healthcare facilities, the existence of key pharma companies, and the rising prevalence of autoimmune diseases are augmenting the demand for methotrexate solutions. The supportive reimbursement policies are further contributing to the overall market growth.
In, the U.S., the increasing cases of cancer coupled with the rise in the stressful lifestyles of individuals is pushing the demand for effective treatment formulations such as methotrexate. The National Cancer Institute reveals that in 2024, an estimated 2.0 million new cancer cases were diagnosed in the U.S. Furthermore, manufacturers’ continuous investments in R&D are leading to the development of innovative methotrexate drug formulations, uplifting the country’s position in the regional market.
In Canada, the strong presence of research organizations such as the Canadian Cancer Society, the Canadian Breast Cancer Foundation, and the Canadian Institutes of Health Research and the government’s supportive policies for drug discovery are augmenting the methotrexate market growth. For instance, in November 2024, McMaster University revealed that it received around USD 4.0 million from the government for the upgradation and future-proofing of its drug discovery infrastructure.
Asia Pacific Market Statistics
The Asia Pacific methotrexate market is anticipated to expand at the fastest pace during the forecast period. The increasing expansion of international pharma companies, the growing governments’ investments in advancing their medical baskets, and rising investments in R&D for the development of effective autoimmune disorders are set to propel the sales of methotrexate solutions in the coming years. China, India, South Korea, and Japan are high-earning marketplaces for methotrexate producers.
In India, the rising cases of cancer are generating robust strides for the adoption of methotrexate drugs. For instance, according to the National Institutes of Health (NIH), cancer cases are set to rise from 1.4 million in 2022 to 1.5 million by 2025, in India. The government’s support for the expansion of the pharma sector is anticipated to boost the production of methotrexate drugs in the country. The India Brand Equity Foundation (IBEF) reveals that the government under its Strengthening of Pharmaceutical Industry (SPI) scheme invested around USD 60.,9 million to enhance the productivity, quality, and sustainability of the existing pharma clusters and MSMEs in the country.
In China, the rising population of senior citizens who are more susceptible to autoimmune disorders such as cancer and arthritis is fueling the consumption of methotrexate drugs. The government's increasing investments in advancing its healthcare facilities are creating lucrative opportunities for methotrexate market.
Key players in the methotrexate market are employing several organic and inorganic tactics such as new product launches, technological innovations, investments in R&D, strategic collaborations & partnerships, mergers & acquisitions, and global expansions to earn high profits and maximize their presence. Industry giants are collaborating with research organizations and partnering with other players to develop innovative methotrexate drug formulations. They are also acquiring smaller pharma companies or start-ups with advanced methotrexate formulations to expand their product offering at minimum CAPEX. Furthermore, the regional expansion tactics are aiding them to grab untapped opportunities.
Some of the key players include in methotrexate market:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?